⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of HyperMabs Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
HyperMabs Inc.
↗Montreal, Canada
HyperMabs Inc. is a Montreal-based biopharmaceutical company specializing in the design and development of innovative monoclonal antibody-based therapeutics. The company focuses on addressing life-threatening diseases, including COVID-19 and various lung diseases, by leveraging cutting-edge protein engineering technologies.
HyperMabs operates with a mission to translate rigorous scientific research into transformative medicines. Their approach involves the incubation of novel therapeutic ideas and rapidly advancing promising candidates from discovery through preclinical and clinical validation, often collaborating with academic institutions to accelerate their pipeline.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Monoclonal Antibody Therapeutics
SIZE & FINANCIALS
Employees:1-50
Revenue:$1M-$2M
Ownership:private
Status:operating
FUNDING
Total Raised:$0
PIPELINE
Stage:Discovery
Lead Drug Stage:Preclinical
Modalities:mAb, Protein biologics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:McGill University (Academic collaboration for biodistribution studies)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Gilles Tremblay - VP of Preclinical Development
Thomas P. Loisel - Vice President of Manufacturing
Julia Schoelermann - Director, Translational Science
LINKS
Website:hypermabs.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with HyperMabs Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.